Literature DB >> 15711788

Pustular skin lesions in patients treated with infliximab: report of two cases.

M J F Starmans-Kool1, H R M Peeters, H H M L Houben.   

Abstract

Two cases are presented in which repeated use of the TNF-alpha blocker infliximab may have led to development of pustular skin lesions. These findings might result in an improved understanding regarding the safety of infliximab with long-term usage.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15711788     DOI： 10.1007/s00296-004-0567-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  15 in total

1.  [Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab].

Authors:  Geoffroy Vanbiervliet; Rodolphe Anty; Stéphane Schneider; Kamel Arab; Patrick Rampal; Xavier Hebuterne
Journal:  Gastroenterol Clin Biol       Date:  2002-03

Review 2.  Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  BioDrugs       Date:  2002       Impact factor: 5.807

Review 3.  Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors.

Authors:  O Kaipiainen-Seppänen; M Leino
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 4.  Review article: safety of infliximab in clinical trials.

Authors:  S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

5.  Neutrophilic dermatosis (pustular vasculitis) of the dorsal hands: a report of 7 cases and review of the literature.

Authors:  David J DiCaudo; Suzanne M Connolly
Journal:  Arch Dermatol       Date:  2002-03

6.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors:  U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

7.  Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.

Authors:  William J Shergy; Reuben A Isern; David A Cooley; John L Harshbarger; J Eugene Huffstutter; Gordon M Hughes; Elizabeth A Spencer-Smith; Allan L Goldman; Sanford H Roth; J Scott Toder; Diana Warner; Adrienne Quinn; Gregory F Keenan; Thomas F Schaible
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

8.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

9.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

Review 10.  Infliximab for the treatment of rheumatoid arthritis.

Authors:  B Blumenauer; M Judd; G Wells; A Burls; A Cranney; M Hochberg; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2002
View more
  5 in total

1.  [Possibilities and limits for treating psoriasis with biologics. Case reports].

Authors:  A Süss; A Colsman; J C Simon; M Sticherling
Journal:  Hautarzt       Date:  2009-01       Impact factor: 0.751

Review 2.  [Infliximab. Role in the treatment of psoriasis].

Authors:  R Mössner; K Reich
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

3.  The changing face of spondyloarthropathies under TNF α blockade.

Authors:  Ori Elkayam; Irena Litinsky; David Levartovsky; Dan Caspi
Journal:  Open Rheumatol J       Date:  2008-11-14

4.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  M J Harrison; W G Dixon; K D Watson; Y King; R Groves; K L Hyrich; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-04-02       Impact factor: 19.103

5.  Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.

Authors:  Rotraut Mössner; Diamant Thaci; Johannes Mohr; Sylvie Pätzold; Hans Peter Bertsch; Ullrich Krüger; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2008-02-01       Impact factor: 3.017
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.